Exploring Type I Interferonopathies: From Molecular Signatures to Clinical Implications
By
Ismail Yaz
Seza Ozen
Hacer N. Bildik
Canberk Ipsir
Dilara Unal
Saliha Esenboga
Begum Cicek
Mehmet E. Seker
Fatima Aerts-Kaya
Seher Sener
Mehmet O. Erkan
Hanife Avci
Deniz Cagdas
Ilhan Tezcan
June 22, 2026
Clinical Scorecard: Exploring Type I Interferonopathies: From Molecular Signatures to Clinical Implications
At a Glance
Category Detail
Condition Type I Interferonopathies Key Mechanisms Dysregulated IFN-I signaling Target Population Patients with clinical or genetic findings consistent with type I interferonopathies Care Setting Clinical and research settings focusing on immunology and pediatric rheumatology
Key Highlights
Type I interferonopathies are heterogeneous diseases. Diagnosis involves assessing clinical/molecular variability. IFN signature and CXCL10 levels are key diagnostic tools. Forty-six patients were studied for clinical and genetic profiles. RT-qPCR was used to assess IFN signature and related cytokines. Guideline-Based Recommendations
Diagnosis
Utilize IFN signature and CXCL10 levels for diagnosis. Management
Management strategies should be tailored based on individual patient profiles. Monitoring & Follow-up
Regular monitoring of IFN-I signaling and associated biomarkers is recommended. Risks
Clinical variability may complicate diagnosis and management. Patient & Prescribing Data
Patients with suspected enhanced IFN-I signaling.
Treatment should consider the heterogeneity of the disease.
Clinical Best Practices
Incorporate molecular profiling in the diagnostic process. Assess both clinical and genetic findings for comprehensive evaluation. Engage in multidisciplinary approaches for management. Related Resources & Content
